ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Precision Neuroscience Expands Clinical Research in Brain–Computer Interface Through Collaboration with Beth Israel Deaconess Medical Center

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation, a pioneering brain–computer interface (BCI) company, today announced a clinical research project with Beth Israel Deaconess Medical Center (BIDMC), a leading teaching hospital affiliated with Harvard Medical School. The collaboration aims to record and analyze brain activity at high resolution in patients undergoing craniotomy procedures, advancing scientific understanding of how the brain governs complex behaviors.

At the core of this groundbreaking research is Precision’s proprietary technology, the Layer 7 Cortical Interface––a revolutionary implant featuring 1,024 ultra-thin electrodes distributed across a flexible 1.5 cm2 film. Designed to conform seamlessly to the brain’s surface, the device captures neural activity with an unprecedented level of detail.

“Partnering with world-renowned institutions like BIDMC is central to our mission of advancing the science behind brain-computer interfaces to improve neurological care,” said Jayme Strauss, Chief Commercial and Clinical Officer at Precision Neuroscience. “This collaboration will provide critical neural data to drive the development of transformative therapies and unlock new possibilities for patients with neurological conditions.”

Precision will work closely with BIDMC’s esteemed research team, led by Dr. Joshua Aronson, M.D., F.A.A.N.S., Director of Epilepsy Surgery. The study will assess the performance of the Layer 7 Cortical Interface during planned craniotomy procedures by placing the device over the brain’s surface to record neural activity associated with specific functional tasks.

“Gaining insight into the brain’s electrical signals at this level of resolution opens new possibilities for developing precise, individualized treatments,” said Dr. Aronson. “We are thrilled to collaborate with Precision Neuroscience to explore how their technology can advance both research and clinical care.”

This collaboration builds on Precision Neuroscience’s robust portfolio of clinical research partnerships with leading medical institutions, including West Virginia University’s Rockefeller Neuroscience Institute, Mount Sinai Health System, and Perelman School of Medicine at the University of Pennsylvania.

The Layer 7 is an investigational device that is not available for sale in the United States.

About Precision:
Precision Neuroscience is working to provide breakthrough treatments for the millions of people worldwide suffering from neurological illnesses. The company is building the only brain–computer interface designed to be minimally invasive, safely removable, and capable of processing large amounts of data. To learn more about how Precision is connecting human intelligence and artificial intelligence, visit www.precisionneuro.io.

Contact
media@precisionneuro.io


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.